PFEPfizer
Pfizer Inc. is a research-based, global biopharmaceutical company. 10-K, Item 1
- Employees
- 75,000
- Headquarters
- New York, NY
- CEO
- Albert Bourla
- Next results
- around Feb 2, 2027
What changed
10-K filed Feb 26, 2026 against Feb 27, 2025| Area | What changed | Source |
|---|---|---|
| Risk factors | 6 new paragraphs, nothing like them in the previous 10-K | 10-K Item 1A |
| Accounting checks | 11 other checks clear | 10-K · XBRL |
| Insiders | 1 open-market buy in the last 90 days | Form 4 |
| Filings | 3 in the last 30 days | EDGAR |
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
What's new, in their words
10-K filed Feb 26, 2026Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-27. Quoted as filed.
Some payers are directing beneficiaries to third-party patient assistance programs, rather than covering certain treatments. In other instances, insurers disallow manufacturers’ co-pay assistance from counting toward reaching the deductible or out-of-pocket maximum. Both approaches can delay access to treatment or result in treatment…
10-K, Item 1A
Accounting checks
latest 10-K11 of 11 clear 0 worth a look. Checks, not verdicts.
- ✓Receivables +3.6% vs revenue -1.6% (+5.2 pts)
- ✓Cash from operations $11.7B vs net income $7.8B (FY ending 2025-12-31)
- ✓Inventory -1.8% vs revenue -1.6% (-0.2 pts)
- ✓Same auditor in both 10-Ks: KPMG LLP
- ✓No statement of substantial doubt about going concern
- ✓No 8-K item 4.02 in the last 2 years
- ✓No NT 10-K or NT 10-Q in the last 2 years
- ✓The same matters as last year: Evaluation of the U.S. Medicare, Medicaid, and performance-based contract rebates accrual; Evaluation of gross unrecognized tax benefits
- ✓No sentence in the 10-K concludes that controls were not effective because of a material weakness
- ✓No 8-K item 2.06 in the last 2 years
- ✓No 8-K item 1.03 in the last 2 years
In the last 30 days
All filings →- Nov 3, 2026Officer CFO change (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”).
- Nov 3, 20268-K Quarterly results 8-K item 2.02
- Nov 3, 202610-Q Quarterly report (10-Q) period ended Sep 27, 2026
Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q.
RSS feed
Work on PFE in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/PFE/export.csv") into a cell.